Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | EIF4A3 | P38919 | 2/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL353311 | 0.80 | PIN1 (0.44) | KDM4EEIF4A3HCAR3HCAR2CYP1A2 | |
| SCHEMBL10856150 | 0.78 | ALDH1A1 (0.40) | KDM4ECYP1A2MAPK1CYP2C19PIN1 | |
| SCHEMBL3023228 | 0.74 | HSP90AA1 (0.39) | KDM4ECYP1A2MAPK1CASP1CYP2C19 | |
| SCHEMBL19077882 | 0.72 | PIN1 (0.47) | KDM4EHCAR2PIN1 | |
| SCHEMBL10710790 | 0.71 | GPR35 (0.37) | CYP1A2MAPK1CASP1CYP2C19PIN1 | |
| SCHEMBL11507890 | 0.71 | ALDH1A1 (0.39) | KDM4EHCAR2CYP1A2MAPK1CASP1 | |
| SCHEMBL2902143 | 0.68 | P2RX3 (0.39) | KDM4ECYP1A2MAPK1CYP2C19PIN1 | |
| SCHEMBL798499 | 0.67 | KDM4E (0.34) | KDM4EGSK3BLMNAHSD17B10 | |
| SCHEMBL4752688 | 0.67 | HPGD (0.41) | KDM4EMAPK1PIN1LMNAHSD17B10 | |
| SCHEMBL17481287 | 0.67 | PARP1 (0.33) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5811445-A | ANGIOTENSIN II INHIBITORS | ROUSSEL UCLAF (FR) | 1998-09-22 | — | — | US | claimed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| US-5811445-A | ANGIOTENSIN II INHIBITORS | ROUSSEL UCLAF (FR) | 1998-09-22 | — | — | US | disclosed |
| US-4146724-A | PROCESS FOR THE MANUFACTURE OF ISOPROPYL 4-METHYLIMIDAZOLE-5-CARBOXYLATE | BASF AKTIENGESELLSCHAFT (DE) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216746-A1 | CHEMICAL COMPOUNDS | SAMHD1, POLRMT, NUDT1 | KDM4E 1070/4885EIF4A3 1239/4885HCAR3 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.